September 07, 2012 08:05 ET

Equity Research on Celgene Corp. and Gilead Sciences Inc. -- Positive Tests and FDA Approvals Buoy Biotechnology Companies

NEW YORK, NY--(Marketwire - Sep 7, 2012) - has a handpicked team of market professionals with over 100 years of combined investing experience. Today they are providing members comprehensive research on the Biotechnology industry and are offering free analytical research on Celgene Corporation (NASDAQ: CELG) and Gilead Sciences Inc. (NASDAQ: GILD). Register with us now to have free access to these research reports. Simply click on the link below.

The biotechnology industry, which features companies such as Celgene Corporation and Gilead Sciences Inc., is generally considered to be relatively well shielded from macroeconomic volatility as health stocks are viewed as essential services. However, industry players often swing as a result of announcements relating to various trials throughout their costly research and development process. Get your free reports on Celgene Corporation and Gilead Sciences Inc. at There is no commitment to join. is the Ultimate Trading Environment for investors. If you are considering owning Celgene Corporation and Gilead Sciences Inc. then you should sign up for a free membership and our complimentary reports today. Over the last 5 years our returns outpaced any of the major indexes. Sign up today by clicking on the link below to find out what you are missing.

Both of the aforementioned companies have made positive announcement relating to their pipeline developments recently. Celgene recently reported the success of its trial showing the effectiveness of its experimental treatment for psoriatic arthritis without any major safety concerns. Celgene Corporation report is accessible for free by registering today at

Meanwhile, Gilead lately announced that Turvada, its once-daily anti-retroviral HIV drug, has been approved by the FDA to be used to limit the spread of the disease between sexual partners, making it the first approved pre-exposure prophylaxis. The company has further gained FDA approval for Stribild, its once-daily HIV combination pill, as a first-line therapy for adult HIV-1 sufferers. Gilead Sciences Inc. report is accessible for free by registering today at

The two Biotechnology stocks research reports are available for free by signing up now on the link below.

Shine's Rooms is the brainchild of David Shine, a 13-year Wall Street veteran with a stellar track record. For 13 years Shine has trained thousands of traders to navigate and profit from the markets. Using cutting-edge technology, Shine provides you with a community in which you can trade alongside Shine and his Team as they guide you through the market's ever-changing landscape.

To view our disclaimer, visit this link

Contact Information